Management of relapse in acute promyelocytic leukaemia treated with up‐front arsenic trioxide‐based regimens

The standard of care for patients with acute promyelocytic leukaemia (APL) relapsing after front‐line treatment with arsenic trioxide (ATO)‐based regimens remains to be defined. A total of 67 patients who relapsed after receiving ATO‐based up‐front therapy and were also salvaged using an ATO‐based r...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouzia, N. A., Sharma, Vibhor, Ganesan, Saravanan, Palani, Hamenth K., Balasundaram, Nithya, David, Sachin, Kulkarni, Uday P., Korula, Anu, Devasia, Anup J., Nair, Sukesh C., Janet, Nancy Beryl, Abraham, Aby, Mani, Thenmozhi, Lakshmanan, Jeyaseelan, Balasubramanian, Poonkuzhali, George, Biju, Mathews, Vikram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological Malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894296/
https://www.ncbi.nlm.nih.gov/pubmed/33216980
http://dx.doi.org/10.1111/bjh.17221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894296/
https://www.ncbi.nlm.nih.gov/pubmed/33216980
http://dx.doi.org/10.1111/bjh.17221

Ejemplares similares